Small Cell Lung Cancer
Conditions
Brief summary
This study was a single-arm, multi-center, phase II study, which is aimed to evaluate the efficacy and safety of CM082 combined with JS001 as the second-line treatment of advanced small cell lung cancer. Eligible patients will receive CM082 tablets 150mg once daily orally in combination with JS001 (240mg, intravenously) every 21 days. Treatment continues until disease progresses , intolerable toxicity, or withdraw.
Detailed description
This study was a single-arm, multi-center, phase II study, which is aimed to evaluate the efficacy and safety of CM082 combined with JS001 as the second-line treatment of advanced small cell lung cancer. Eligible patients will receive CM082 tablets 150mg once daily orally in combination with JS001 (240mg, intravenously) every 21 days. Treatment continues until disease progresses , intolerable toxicity, or withdraw. The primary endpoint is tumor response per investigator assessment according to response evaluation criteria in solid tumors (recist) version 1.1, secondary endpoints include disease control rate, progression-free survival, overall survival, safety and tolerability. iRECIST is also implemented for tumor response assessment.
Interventions
DRUGCM082 plus JS001
CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Sponsors
AnewPharma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed recurrent, inoperable, metastatic SCLC (stage III/IV period); * Progressive disease after prior standard systemic treatment; * Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1; * Life expectancy of at least 12 weeks; * At least one measurable lesion according to the RECIST 1.1; * Adequate organ functions; * Negative serum pregnancy test results within 7 days prior to the first dose of the study drug; * Patients willing to obey the schedule for study and follow-up procedures; * Patients who can understand the nature of the study and sign voluntarily the informed consent.
Exclusion criteria
* Patients who have previously received treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or VEGFR TKI therapy (sunitinib, sorafenib, pizopren, axitinib, bevacizumab, remomituzumab, nidanib, vandetanib, etc), or CTLA-4 inhibitor (Ipilimumab, etc). * Patients who are presently receiving other systematic antitumor therapies. * Patients who developed other malignancies (not including cured basal cell tumor of skin, endoscopically resected early gastrointestinal tract \[GI\] tumor, and cervical carcinoma in situ) except lung cancer in the past 2 years. * Patients receiving a major surgery or immunotherapy in the past 4 weeks prior to the first dose; and patients receiving a radiotherapy within 2 weeks prior to the first dose. * Patients with brain metastases or meningeal metastases. * Have received hematopoietic stimulating factors within 1 week prior to the first dose of the study drug. * Patients who previously received stem cell transplantation or organ transplantation. * Patients with swallowing dysfunction, active gastrointestinal disease, or other disorders that may influence significantly absorption, distribution, metabolism, or excretion of CM082. * Patients with active hepatitis B, hepatitis C virus antibody positive , HIV antibodies, or treponema pallidum antibody positive. * Patients with a prior history of interstitial lung disease, history of drug-induced interstitial lung disease, history of radiation pneumonia requiring a steroid therapy, or any clinical indications for active interstitial lung disease. * Patients who are known to be allergic to JS001 or CM082 or any excipients of the study drugs. * Patients receiving in the past 14 days or requiring concurrently the following drugs during treatment: Drugs that may result in a risk for QTc prolongation and/or torsades de pointes; or CYP3A potent inhibitors or potent inducers. * Patients with other severe, acute or chronic medical conditions (including incontrollable diabetes mellitus, or medical disease or mental disease, or laboratory test abnormality) that may increase study-related risk or may interfere with interpretation of the research results, in the viewpoints of the investigator. * Patients with other conditions that not suitable to participate in this study, as considered by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 6 months | The proportion of patients with complete remission (CR) and partial remission (PR) in all patients. Disease progression will be evaluated according to RECIST 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | 12 months | The internal between the date of enrollment and the date of disease progression, unaccepted toxicity, or death according to RECIST 1.1 and iRECIST. |
| Overall survival | 36 months | The internal between the date of randomization and the date of death |
| Disease Control Rate | 6 months | The proportion of patients with complete remission (CR), partial remission (PR) and stable disease (SD) in all patients. Disease progression will be evaluated according to RECIST 1.1 and iRECIST. |
| Duration of Response | 12 months | The time between patients's first time to complete or partial remission to disease progression. |
| Time to response | 12 months | The internal between the date of enrollment and the date of documented tumor response |
Countries
China
Contacts
Primary ContactYuankai Shi, MD
Outcome results
None listed